Sea, carbohydrates and clotting: A triad on the road of drug discovery

Mini-Reviews in Medicinal Chemistry

Volumn 14, Issue 9, 2014, Pages 717-724

  Pomin, Vitor H ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Anticoagulation; Antithrombosis; Carbohydrate based drug development; Sulfated fucans; Sulfated galactans; Sulfation patterns

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5A; CARBOHYDRATE; DERMATAN SULFATE; FIBRIN; FUCAN SULFATE; GALACTAN; GLYCAN; HEPARIN; POLYSACCHARIDE SULFATE; PROTHROMBIN A; THROMBIN; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; FUCOIDIN; POLYSACCHARIDE;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CHEMICAL STRUCTURE; DRUG BIOAVAILABILITY; HUMAN; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; SEA; SEA CUCUMBER; SEA URCHIN; SULFATION; THROMBUS; ANIMAL; CARDIOVASCULAR DISEASES; CHEMISTRY; COMPLICATION; DRUG DEVELOPMENT; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; CARDIOVASCULAR DISEASES; DERMATAN SULFATE; DRUG DISCOVERY; FIBRINOLYTIC AGENTS; GALACTANS; HEPARIN; HUMANS; POLYSACCHARIDES; SEA CUCUMBERS; SEA URCHINS;

EID: 84911487939     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557514666140820121048     Document Type: Article

References (62)

1. World Health Organization. Media Centre: The top 10 causes of deaths. www. who. int/mediacentre/factsheets/fs310/en/ (Accessed July 25, 2014).
2. World Health Organization. Media Centre: The top 10 causes of deaths. www. who. int/mediacentre/factsheets/fs310/en/index2. html (Accessed July 25, 2014).
3. Centers for Disease Control and Prevention. FastStats: Deaths and Mortality. www. cdc. gov/nchs/fastats/deaths. htm (Accessed July 25, 2014).
4. Buttar, H. S.; Li, T.; Ravi, N. Prevention of cardiovascular diseases: Role of exercise, dietary interventions, obesity and smoking cessation. Exp. Clin. Cardiol., 2005, 10, 229-249.
5. Johnson, C. M.; Mureebe, L.; Silver, D. Hypercoagulable states: a review. Vasc. Endovascular Surg., 2005, 39, 123-133.
6. Kwaan, H. C.; Samama, M. M. Anticoagulant drugs: an update. Expert Rev. Cardiovasc. Ther., 2004, 2, 511-522.
7. Schummacher, W. A.; Luettgen, J. M.; Quan, M. L.; Seiffert, D. A. Inhibition of factor Xia as a new approach to anticoagulation. Arterioscler. Thromb. Vasc. Biol., 2010, 30, 388-392.
8. Tan, K. T.; Lip, G. Y. Fondaparinux. Curr. Pharm. Des., 2005, 11, 415-419.
9. Xiang, Y. Z.; Xia, Y.; Gao, X. M.; Shang, H. C.; Kang, L. Y.; Zhang, B. L. Platelet activation, and antiplatelet targets and agents: current and novel strategies. Drugs, 2008, 68, 1647-1664.
10. Gallus, A. S. Aspirin and other platelet-aggregation inhibiting drugs. Med. J. Aust. 1985, 142, 41-47.
11. Lijnen, H. R.; Collen, D. Fibrinolytic agents: mechanisms of activity and pharmacology. Thromb. Haemost., 1995, 74, 387-390.
12. Pomin, V. H.; Park, Y. The science of the repeating disaccharide-composed glycosaminoglycans. 2012 At Advances in chemistry research. Volume 12. Nova Science Publishers. Editor James C. Taylor. Pgs 1-64.
13. Capila I.; Linhardt R. J. Heparin-protein interactions. Angew. Chem. Int. Ed. Engl., 2002, 41, 390-412.
14. Pomin, V. H.; Piquet, A. A.; Pereira, M. S.; Mourão, P. A. Residual keratan sulfate in chondroitin sulfate formulations for oral administration. Carbohydr. Pol., 2012, 90, 839-846.
15. Hyers, T. M.; Agnelli, G.; Hull, R. D.; Morris, T. A.; Samama, M.; Tapson, V.; Weg, J. G. antithrombotic therapy for venous thromboembolic disease. Chest., 2001, 119, 176S-193S.
16. Norma, R. 100 years. Looking back. Skill, drive and luck: the discovery and development of heparin. CMAJ., 2011, 13, 2139-2140.
17. Mulloy, B.; Gray, E.; Barrowcliffe, T. W. Characterization of unfractionated heparin: comparison of materials from the last 50 years. Thromb. Haemost., 2000, 84, 1052-1056.
18. Tagarakis, G.; Tsilimingas, N. B. Heparin-coated extracorporeal circulation systems in heart surgery. Rec. Pat. Cardiovasc. Drug Discov., 2009, 4, 177-179.
19. Molito, B.; Kingel R.; Hafner, G. Monitoring of the heparin therapy during acute haemodialysis. Hamostaseologie. 2005, 25, 272-278.
20. Gray, E.; Mulloy, B.; Barrowcliffe, T. W. Heparin and low-molecular-weight heparin. Thromb. Haemost., 2008, 99, 807-818.
21. Santos, G. R.; Tovar, A. M.; Capillé, N. V.; Pereira, M. S.; Pomin, V. H.; Mourão, P. A. Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs. Drug Discov. Today, 2014, in press.
22. Barrowcliffe, T. W. History of heparin. In: Heparin-A Century of Progress; Lever, R.; Mulloy, B.; Page, C. P.; Ed.; Springer Berlin Heidelberg, 2012, 207, pp. 4-19.
23. Aquino, R. S.; Pereira, M. S.; Vairo, B. C.; Cinelli, L. P.; Santos, G. R.; Fonseca, R. J.; Mourão, P. A. Heparins from porcine and bovine inestinal mucosa: Are they similar drugs? Thromb. Haemost., 2010, 103, 1005-1015.
24. Rabenstein, D. L. Heparin and heparan sulfate: structure and function. Nat. Prod. Rep., 2002, 19, 312-331.
25. Warkentin, T. E. Heparin-induced thrombocytopenia: a clinicopathologic genesis. Thromb. Haemost., 1999, 82, 439-47.
26. Visentin, G. P. Heparin-induced thrombocytopenia: molecular pathogenesis. Thromb. Haemost., 1999, 82, 448-56.
27. Kelton, J. G. Hirsh, J. Bleeding associated with antithrombotic therapy. Semin. Hematol., 1980, 17, 259-379.
28. Kakkar, V. V.; Kakkar, S.; Sanderson, R. M.; Peers, C. E. Efficacy and safety of two regimens of low molecular weight heparin fragment Fragmin in preventing post-operative venous thromboembolism. Haemostasis, 1986, 16, 19-24.
29. Weitz, J. I. Low-molecular-weight heparins. N. Engl. J. Med., 1992, 337, 688-98.
30. Nishino, T.; Fukuda, A.; Nagumo, T.; Fujihara, M.; Kaji, E. Inhibition of the generation of thrombin and factor Xa by a fucoidan from the brown seaweed Ecklonia kurome. Thromb. Res., 1999, 96, 37-49.
31. Husted, S. E.; Nielsen, H. K. Unfractionated heparin and low molecular weight heparin for acute coronary syndromes-assessment of a Cochrane review. Ugeskr. Laeger, 2010, 172, 2888-2891.
32. Mourão, P. A. Use of sulfated fucans as anticoagulant and antithrombotic agents: future perspectives. Curr. Pharm. Des., 2004, 10, 967-981.
33. Kishimoto, T. K.; Viswanathan, K.; Ganguly, T.; Elankumaran, S.; Smith, S.; Pelzer, K.; Lansing, J. C.; Sriranganathan, N.; Zhao, G.; Galcheva-Gargova, Z.; Al-Hakim, A.; Bailey, G. S.; Fraser, B.; Roy, S.; Rogers-Cotrone, T.; Buhse, L.; Whary, M.; Fox, J.; Nasr, M.; Dal Pan, G. J.; Shriver, Z.; Langer, R. S.; Venkataraman, G.; Austen, K. F.; Woodcock, J.; Sasisekharan, R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N. Engl. J. Med., 2008, 358, 2457-67.
34. Guerrini, M.; Beccati, D.; Shriver, Z.; Naggi, A.; Viswanathan, K.; Bisio, A.; Capila, I.; Lansing, J. C.; Guglieri, S.; Fraser, B.; Al-Hakim, A.; Gunay, N. S.; Zhang, Z.; Robinson, L.; Buhse, L.; Nasr, M.; Woodcock, J.; Langer, R.; Venkataraman, G.; Linhardt, R. J.; Casu, B.; Torri, G.; Sasisekharan, R. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol., 2008, 26, 669-675.
35. Larive, C. K. New developments in the characterization of heparin and its impurities. Anal. Bioanal. Chem., 2011, 399, 525-526.
36. Liu, H.; Zhang, Z.; Linhardt, R. J. Lessons learned from the contamination of heparin. Nat. Prod. Rep., 2012, 26, 313-321.
37. Laurencin, C. T.; Nair, L. The FDA and safety--beyond the heparin crisis. Nat. Biotechnol., 2008, 26, 621-623.
38. Lavine, G. Tainted heparin crisis tested FDA's investigative skills. Am. J. Health Syst. Pharm., 2009, 66, 210-211.
39. Sasisekharan, R.; Shriver, Z. From crisis to opportunity: a perspective on the heparin crisis. Thromb. Haemost., 2009, 102, 854-858.
40. Rosania, L. Heparin crisis 2008: a tipping point for increased FDA enforcement in the pharma sector? Food Drug Law J., 2010, 65, 489-501.
41. Pomin, V. H.; Mourão, P. A. Structure, biology, evolution, and medical importance of sulfated fucans and galactans. Glycobiol., 2008, 18, 1016-1027.
42. Pomin, V. H.; Mourão, P. A. Specific sulfation and glycosylation-a structural combination for the anticoagulation of marine carbohydrates. Front. Cell. Infect. Microbiol., 2014, 4, 33.
43. Pomin, V. H. Marine Medicinal Glycomics. Front. Cell. Infect. Microbiol., 2014, 4, 5.
44. Pomin, V. H. Fucanomics and galactanomics: marine distribution, medicinal impact, conceptions, and challenges. Mar. Drugs, 2012, 10, 793-811.
45. Pomin, V. H. Fucanomics and galactanomics: current status in drug discovery, mechanism of action and the role of the well-defined structures. Biochim. Biophys. Acta, 2012, 1820, 1971-1979.
46. Pomin, V. H. Holothurian chondroitin sulfate. Mar. Drugs, 2014, 12, 232-254.
47. Pavão, M. S.; Aiello, K. R.; Werneck, C. C.; Silva, L. C.; Valente, A.-P.; Mulloy, B.; Colwell, N. S.; Tollefsen, D. M.; Mourão, P. A. Highly sulfated dermatan sulfates from ascidians. Structure versus anticoagulant activity of these glycosaminoglycans. J. Biol. Chem., 1998, 273, 27 848-27857.
48. Bourin, M. C.; Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem. J., 1993, 289, 313-30.
49. Pomin, V. H. How to analyze the anticoagulant and antithrombotic mechanism of action in fucanome and galactanome? Glycoconj. J., 2014, 31, 89-99.
50. Pereira, M. S.; Melo, F. R.; Mourão, P. A. Is there a correlation between structure and anticoagulant action of sulfated galatans and sulfated fucans? Glycobiol. 2002, 12, 573-580.
51. Pomin, V. H. Review: An overview about the structure-function relationship of marine sulfated homopolysaccharides with regular chemical structures. Biopol., 2009, 91, 601-609.
52. Glauser, B. F.; Mourão, P. A.; Pomin, V. H. Marine sulfated glycans with serpin-unrelated anticoagulant properties. Adv. Clin. Chem., 2013, 62, 269-303.
53. Glauser, B. F.; Pereira, M. S.; Monteiro, R. Q.; Mourão, P. A. Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate. Thromb. Haemost., 2008, 100, 420-428.
54. Glauser, B. F.; Rezende, R. M.; Melo, F. R.; Pereira, M. S.; Francischetti, M.; Monteiro, R. Q.; Rezaie, A. R.; Mourão, P. A. Anticoagulant activity of a sulfated galactan: serpin-independent effect and specific interaction with factor Xa. Thromb. Haemost., 2009, 102, 1183-93.
55. Quinderé, A. L.; Santos, G. R.; Oliveira, S. N.; Glauser, B. F.; Fontes, B. P.; Queiroz, I. N.; Benevides, N. M., Pomin, V. H., Mourão, P. A. Is the antithrombotic effect of sulfated galacatns independent of serpin? J. Thromb. Haemost., 2014, 12, 43-53.
56. Fonseca, R. J. Mourão, P. A. Fucosylated chondroitin sulfate as a new oral antithrombotic agent. Thromb. Haemost., 2006, 96, 822-829.
57. Mourão, P. A., Guimarães, B., Mulloy, B., Thomas, S., Gray, E. Antithrombotic activity of a fucosylated chondroitin sulphate from echinoderm: sulphated fucose branches on the polysaccharide account for its antithrombotic action. Br. J. Haematol., 1998, 101, 647-652.
58. Pomin, V. H. Structure-function relationship of anticoagulant and antithrombotic well-defined sulfated polysaccharides from marine invertebrates. Adv. FoodNutr. Res., 2012, 65, 195-209.
59. Pereira, M. S.; Vilela-Silva, A.-C.; Valente, A.-P.; Mourão, P. A. A 2-sulfated, 3-linked alpha-L-galactan is an anticoagulant polysaccharide. Carbohydr. Res., 2002, 337, 2231-2238.
60. Fonseca, R. J.; Santos, G. R.; Mourão, P. A. Effects of polysaccharides enriched in 2, 4-disulfated fucose units on coagulation, thrombosis and bleeding. Practical and conceptual implications. Thromb. Haemost., 2009, 102, 829-836.
61. Pereira, M. G.; Benevides, N. M.; Melo, M. R.; Valente, A.-P.; Melo, E. R.; Mourão, P. A. Structure and anticoagulant activity of a sulfated galactan from the red alga, Gelidium crinale. Is there a specific structural requirement for the anticoagulant action? Carbohydr. Res., 2005, 340, 2105-2023.
62. Luo, L.; Wu, M.; Xu, L.; Lian, W.; Xiang, J.; Lu, F.; Gao, N.; Xiao, C.; Wang, S.; Zhao, J. Comparison of physicochemical characteristics and anticoagulant activities of polysaccharides from three sea cucumbers. Mar. Drugs, 2013, 11, 399-417.